Event · terminal · Newsmetry

newsmetry

Probability95%

24h change+0.3 pp

24h volume$963.07K

Liquidity$666.31K

Ends31 Dec 2026

VenuePolymarket ↗

News on chart · 54

…

Places Yes bids below the midpoint and No bids below its mirror: two-sided liquidity without holding shares first. Orders inside the reward zone earn a share of Polymarket's daily pool while they rest.

Midpoint: 94.8¢
Rewards: max spread 5.5¢ · min size 200

LevelsShares per levelOffset from mid, ¢Step, ¢

Orders	Price	Shares	$
Buy Yes	93.7¢	200	187.40	✓
Buy Yes	92.7¢	200	185.40	✓
Buy Yes	91.7¢	200	183.40	✓
Buy No	4.2¢	200	8.40	✓
Buy No	3.2¢	200	6.40	✓
Buy No	2.2¢	200	4.40	✓

Capital needed: $575.40
in reward zone: 6 / 6
Newsmetry fee: 0%

Connect a wallet to see positions and orders

11-13 13:42·Euroseas and Similarweb report on November 17: what analysts expect
11-12 18:56·Barclays Cuts Nayax Price Target to $60 From $68
11-12 14:56·Nano Dimension and Stratasys Call Off $42.5 Million Markforged Sale
11-12 13:18·Piper Sandler lifts price targets on Jazz and Teva shares
11-12 12:50·JP Morgan Lowers Innoviz Technologies Rating to Neutral
11-12 13:09·Inhibikase and Fennec Pharmaceuticals release quarterly results for September
11-12 12:05·Mobility Global Lifts Q3 Revenue 7.4% and Authorizes $800 Million Buyback
11-12 05:20·Delta Galil Q3 sales reach record high as dividend rises 25%
11-11 21:07·UBS cuts Tronox price target to $2.75 and keeps Neutral rating
11-11 18:31·Radcom Stock Jumps 10% as Company Keeps Guidance and Eyes 2027 Rebound
11-11 17:07·Nayax Shares Rise as Raised Outlook Follows IPS Acquisition
11-11 16:40·Piper Sandler upgrades Alpha Tau Medical to Overweight and lifts target to $22
11-11 19:23·Nissan: average 12-month price target trimmed to JPY 377.81
11-11 16:24·Nayax Q3 revenue rises 23% with record 49.6% gross margin
11-11 15:27·Barclays keeps Dauch at Equal-Weight and cuts price target to $6 from $8
11-11 13:24·Teva targets $6–7 billion innovative medicines revenue by 2030
11-11 12:17·Radcom Q3 revenue beats estimates but falls 23.6% year on year
11-11 12:10·Radcom and Caesarstone report Q3 results: one profit, one large loss
11-11 10:15·ICL Group Q3 revenue rises 3.1% as profit edges higher
11-11 10:19·Needham Cuts Price Targets on D-Wave Quantum and Gilat Satellite Shares
11-11 10:17·Needham Keeps Buy on Liquidia and Ambiq Micro, Adjusts Both Targets
11-11 08:46·BEZQ: core revenue growth and new subscribers support expanded infrastructure investment
11-10 21:09·CoreWeave raises 2026 revenue guidance as third-quarter sales more than double
11-10 20:27·William Blair cuts Gilat Satellite Networks to Market Perform from Outperform
11-10 19:32·Tel Aviv Stock Exchange posts record nine-month results and targets 15–18% revenue growth
11-10 17:33·Safilo and BFF Bank start earnings calls for the third quarter of 2026
11-10 16:14·BWAY lifts revenue, margins and FY26 outlook on steady demand
11-10 16:53·Honda revenue up 12.9%, but adjusted EPS falls short of analyst expectations
11-09 00:06·Carlsmed expected to post 40-cent loss per share on 46.5% revenue growth
11-08 16:14·Berkshire Hathaway Beats Analyst Estimates in Latest Quarterly Results
11-08 11:31·Israir in preliminary talks to buy rival Arkia, Reuters reports
11-07 20:12·Eisenkot gets first chance to form Israel's next government
11-07 19:31·Israeli president tasks Gadi Eisenkot with forming a new government
11-05 20:05·Leerink Partners Raises McKesson Price Target to $1200 a Share
11-05 18:24·RBC Capital keeps ARM at Outperform but cuts target to $300 from $340
11-05 14:17·Citizens cuts price targets on Flutter, LeMaitre Vascular and NICE, keeps ratings
11-05 12:10·Moderna and Nebius to report Q3 results: revenue and EPS consensus
11-05 11:35·Americold Q3 2026: Revenue Up 4.2%, Debt Cut by $1.15 Billion, Guidance Raised
11-05 10:11·Manulife Financial Q3 adjusted EPS beats analyst forecasts
11-05 09:14·ATRenew, Futu, NetEase and Youdao to report Q3 results on November 19
11-03 23:29·International General Insurance tops Q3 EPS estimate with 67 cents
11-03 21:54·Caesarstone Moves Q3 2026 Results to November 11 Amid Legal Talks
11-03 18:34·Morgan Stanley and JP Morgan cut price targets on Check Point Software shares
11-03 16:12·TD Cowen Raises Price Targets for Appian and SBA Communications
11-03 15:43·TD Cowen raises Cheniere Energy price target to $352 from $325
11-03 15:57·Check Point: Barclays and Wells Fargo keep equal-weight rating on shares
11-03 13:57·Sofwave Medical Q3 revenue climbs 35% on usage fee income
11-03 12:25·Teva's new drugs offset generic losses, lifting margins and the 2026 outlook
11-03 12:08·Eight small US companies to report third-quarter results on November 4
11-03 11:02·Needham keeps Buy rating on Upwork and lifts price target to $13
11-01 16:53·Affle to buy Israel's Perion for about $420 million in cash
11-01 12:53·Affle 3i to buy Israel's Perion Network for $420 million in cash
11-01 10:34·Affle to Buy Perion in $420 Million All-Cash Deal at 34.5% Premium
10-31 00:22·BioMarin licenses Fabry disease drug, Teva buys BioXcel neuroscience assets